The update was based on study findings that showed there were no clinically significant differences in levothyroxine pharmacokinetics between Tirosint-SOL administered 15 minutes or 30 minutes ...

CHICAGO—Compounded oral liquid levothyroxine products vary in stability, potency and consistency and present risks for patients, according to data presented the American Thyroid Association ...

Methods: In this prospective open-label study, 17 patients with recently diagnosed primary hypothyroidism due to Hashimoto's thyroiditis who were not taking levothyroxine were included. The ...

In the saline group, only 50 donors (12%) received open-label levothyroxine after the 12-hour trial period, for a median duration of 31 hours (interquartile range, 20-43); reasons for open-label ...

The study authors, from Johns Hopkins Medicine, linked levothyroxine use to a greater loss of bone mass and bone density over six years — even in older adults with normal thyroid function.

If levothyroxine use accelerates bone density loss, the risks of bone fractures and related injuries become a pressing concern for healthcare providers and patients alike. The over-prescription debate ...

Westminster Pharmaceuticals, LLC has instructed wholesalers to stop distributing specific products labeled "Levothyroxine and Liothyronine (Thyroid Tablets, USP)," according to an August 9 release.

A widely prescribed thyroid medication called levothyroxine may cause bone loss and increase the risk of the bone disease osteoporosis, according to new research—but this does not mean Americans ...